Key points are not available for this paper at this time.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes, obesity and cardiovascular health, yet some patients remain hesitant to start these therapies due to perceptions that they are "new" or unproven. This commentary equips clinicians with practical counseling strategies to reframe the "newness" narrative and address long-term safety concerns. We provide a brief history of GLP-1 from its discovery in the 1980s to nearly two decades of clinical use, underscoring that GLP-1RAs are the product of extensive research rather than experimental novelties. We compare native GLP-1 to newer agents like semaglutide and tirzepatide, highlighting structural modifications that prolong action without fundamentally altering the hormone's mechanism. Known safety data are summarized emphasizing the predominance of mild, transient gastrointestinal side effects and the lack of evidence for feared risks like cancer along with how to discuss these points. A practical counseling checklist and sample patient-centric language are included to facilitate shared decision-making. In sum, clinicians can confidently reassure patients that GLP-1RAs are well-studied, mechanism-based therapies with millions of patient-years of experience supporting their safety and efficacy.
Shah et al. (Fri,) studied this question.